A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis

Nobuyasu Ishii, Toshiki Shimizu, Yoshihisa Ishiura, Hideki Amuro, Tohru Nishizawa, Takeshi Tamaki, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Moriguchi-City, Osaka, 570-8507, JapanCorrespondence: Toshiki ShimizuFirst Department of Internal Medicine, Kansai Medic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ishii N, Shimizu T, Ishiura Y, Amuro H, Nishizawa T, Tamaki T, Nomura S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	rheumatoid arthritis tocilizumab c-reactive protein platelet large cell ratio disease control time Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/bbf04dc6e3cf4f208dbc2956ed662950
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bbf04dc6e3cf4f208dbc2956ed662950
record_format	dspace
spelling	oai:doaj.org-article:bbf04dc6e3cf4f208dbc2956ed6629502021-12-02T18:49:13ZA Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis1178-7031https://doaj.org/article/bbf04dc6e3cf4f208dbc2956ed6629502021-08-01T00:00:00Zhttps://www.dovepress.com/a-single-center-retrospective-observational-study-evaluating-the-favor-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Nobuyasu Ishii, Toshiki Shimizu, Yoshihisa Ishiura, Hideki Amuro, Tohru Nishizawa, Takeshi Tamaki, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Moriguchi-City, Osaka, 570-8507, JapanCorrespondence: Toshiki ShimizuFirst Department of Internal Medicine, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi-City, Osaka, 570-8507, JapanTel + 81-6-6992-1001Fax + 81-6-6992-1066Email shimizto@takii.kmu.ac.jpBackground: Tocilizumab (TCZ) is humanized monoclonal antibody against the interleukin-6 (IL-6) and receptor that has prominent efficacy for the treatment of rheumatoid arthritis (RA). We conducted a retrospective observational study to determine how long TCZ controls RA.Patients and Methods: We retrospectively reviewed the medical records of RA patients treated with TCZ. The aim of this study was to evaluate the contribution of clinical parameters to disease control time (DCT) in RA patients.Results: Overall, 144 patients were enrolled in the study. The median age of patients was 66 years (range: 34– 85 years). In univariate analysis, DCT was significantly increased in patients who had never received previous biologic disease-modifying anti-rheumatic drugs treatment (P = 0.0064). We also analyzed the contribution of the base line value of C-reactive protein (CRP) to DCT. We divided the patients with RA into two groups according to a cutoff value of 1.000 mg/dl. The median control times were 77.5 months (95% confidence interval [CI]: 44.8–not reached to median) and 34.5 months (95% CI: 17.0– 79.3) for patients with high and low CRP value, respectively. In univariate analysis, DCT was significantly increased in patients with a high CRP value (P = 0.0283). Multivariate analysis clearly revealed that a high baseline CRP value was an independent favorable predictive factor for longer DCT (hazard ratio, 0.608, 95% CI: 0.378– 0.981, P = 0.0416).Conclusion: These data clearly demonstrate that the baseline value of CRP was closely associated with long time DCT in patients of RA treated with TCZ.Keywords: rheumatoid arthritis, tocilizumab, C-reactive protein, platelet large cell ratio, disease control timeIshii NShimizu TIshiura YAmuro HNishizawa TTamaki TNomura SDove Medical Pressarticlerheumatoid arthritistocilizumabc-reactive proteinplatelet large cell ratiodisease control timePathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 3721-3728 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rheumatoid arthritis tocilizumab c-reactive protein platelet large cell ratio disease control time Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	rheumatoid arthritis tocilizumab c-reactive protein platelet large cell ratio disease control time Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Ishii N Shimizu T Ishiura Y Amuro H Nishizawa T Tamaki T Nomura S A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis
description	Nobuyasu Ishii, Toshiki Shimizu, Yoshihisa Ishiura, Hideki Amuro, Tohru Nishizawa, Takeshi Tamaki, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Moriguchi-City, Osaka, 570-8507, JapanCorrespondence: Toshiki ShimizuFirst Department of Internal Medicine, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi-City, Osaka, 570-8507, JapanTel + 81-6-6992-1001Fax + 81-6-6992-1066Email shimizto@takii.kmu.ac.jpBackground: Tocilizumab (TCZ) is humanized monoclonal antibody against the interleukin-6 (IL-6) and receptor that has prominent efficacy for the treatment of rheumatoid arthritis (RA). We conducted a retrospective observational study to determine how long TCZ controls RA.Patients and Methods: We retrospectively reviewed the medical records of RA patients treated with TCZ. The aim of this study was to evaluate the contribution of clinical parameters to disease control time (DCT) in RA patients.Results: Overall, 144 patients were enrolled in the study. The median age of patients was 66 years (range: 34– 85 years). In univariate analysis, DCT was significantly increased in patients who had never received previous biologic disease-modifying anti-rheumatic drugs treatment (P = 0.0064). We also analyzed the contribution of the base line value of C-reactive protein (CRP) to DCT. We divided the patients with RA into two groups according to a cutoff value of 1.000 mg/dl. The median control times were 77.5 months (95% confidence interval [CI]: 44.8–not reached to median) and 34.5 months (95% CI: 17.0– 79.3) for patients with high and low CRP value, respectively. In univariate analysis, DCT was significantly increased in patients with a high CRP value (P = 0.0283). Multivariate analysis clearly revealed that a high baseline CRP value was an independent favorable predictive factor for longer DCT (hazard ratio, 0.608, 95% CI: 0.378– 0.981, P = 0.0416).Conclusion: These data clearly demonstrate that the baseline value of CRP was closely associated with long time DCT in patients of RA treated with TCZ.Keywords: rheumatoid arthritis, tocilizumab, C-reactive protein, platelet large cell ratio, disease control time
format	article
author	Ishii N Shimizu T Ishiura Y Amuro H Nishizawa T Tamaki T Nomura S
author_facet	Ishii N Shimizu T Ishiura Y Amuro H Nishizawa T Tamaki T Nomura S
author_sort	Ishii N
title	A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis
title_short	A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis
title_full	A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis
title_fullStr	A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis
title_full_unstemmed	A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis
title_sort	single-center retrospective observational study evaluating the favorable predictive factors for the disease control time of treatment with tocilizumab in patients of rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/bbf04dc6e3cf4f208dbc2956ed662950
work_keys_str_mv	AT ishiin asinglecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT shimizut asinglecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT ishiuray asinglecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT amuroh asinglecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT nishizawat asinglecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT tamakit asinglecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT nomuras asinglecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT ishiin singlecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT shimizut singlecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT ishiuray singlecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT amuroh singlecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT nishizawat singlecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT tamakit singlecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis AT nomuras singlecenterretrospectiveobservationalstudyevaluatingthefavorablepredictivefactorsforthediseasecontroltimeoftreatmentwithtocilizumabinpatientsofrheumatoidarthritis
_version_	1718377585945083904

A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis

Ejemplares similares